Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 647 matching trials from the live ClinicalTrials.gov search.
Conditions
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
Interventions
CC-223, erlotinib, CC-223, oral azacitidine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • New York, New York + 4 more
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Bevacizumab, Everolimus, Laboratory Biomarker Analysis, Placebo
Biological · Drug · Other
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
45
States / cities
Phoenix, Arizona • Burbank, California • Los Angeles, California + 32 more
Terminated Early Phase 1 Interventional Results available

Research Study of ATG and Rituximab in Renal Transplantation

NCT01318915
Conditions
Renal Transplant Recipients
Interventions
ATG, Rituximab, Tacrolimus, Sirolimus, MMF
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Conditions
Hepatocellular Carcinoma
Interventions
sorafenib with temsirolimus
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
San Francisco, California • Chicago, Illinois
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

TMLI and Alemtuzumab for Treatment of Sickle Cell Disease

NCT05384756
Conditions
Sickle Cell Disease
Interventions
Alemtuzumab, Hematopoietic Cell Transplantation, Intensity-Modulated Radiation Therapy, Sirolimus
Drug · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Duarte, California
Conditions
Soft Tissue Sarcoma
Interventions
Ribociclib, Everolimus
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Conditions
Neoplasms, Malignant Carcinoma
Interventions
Neratinib, Temsirolimus
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Boston, Massachusetts
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Basal Cell Carcinoma, Metastatic Carcinoma in the Skin, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Unresectable Basal Cell Carcinoma, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Kidney Biopsy, Magnetic Resonance Imaging, Nivolumab, Prednisone, Sirolimus
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
26
States / cities
La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 18 more
Conditions
Adenocarcinoma, Neoplasms
Interventions
Torisel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Year to 21 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 8 more
Conditions
Leukemia, Lymphoma, Non-Hodgkin, Hematologic Diseases, Acute GVHD
Interventions
Sirolimus, MMF, BCNU, VP-16, CY, FTBI, BU
Drug
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Stanford, California
Conditions
Desmoid Tumor
Interventions
Sirolimus
Drug
Lead sponsor
MaineHealth
Other
Eligibility
Up to 29 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Gainesville, Florida + 5 more
Conditions
Age-Related Macular Degeneration
Interventions
Sirolimus
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Solid Tumors
Interventions
Nelfinavir, Nelfinavir Mesylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Longevity, GLP-1, Geroscience, Aging
Interventions
Metformin, Rapamycin, Naltrexone, Vitamin C
Drug · Dietary Supplement
Lead sponsor
AgelessRx
Industry
Eligibility
40 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Age-related Macular Degeneration, Choroidal Neovascularization
Interventions
Sirolimus
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Severe Combined Immunodeficiency, Transplacental Maternal Engraftment, Stem Cell Transplant
Interventions
Sirolimus
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Day to 1 Year
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Francisco, California
Conditions
Metastatic Colorectal Cancer
Interventions
OSI-906, Everolimus
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Fort Myers, Florida • Nashville, Tennessee
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Altering Memories That Increase Risk of Relapse in Alcohol Use Disorders

NCT03732248
Conditions
Alcohol Use Disorder, Alcohol Dependence
Interventions
Rapamycin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Graft Rejection, Kidney Transplant, Renal Allograft Recipients, Renal Transplant
Interventions
Tacrolimus, Sirolimus
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
25
States / cities
La Jolla, California • San Francisco, California • Aurora, Colorado + 19 more
Conditions
Neurofibromatosis Type 1
Interventions
Sirolimus
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
3 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
9
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Conditions
Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
Interventions
Anakinra, Denosumab, Everolimus
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Houston, Texas
Conditions
Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity, Chronic Rejection of Lung Transplant
Interventions
Liposomal aerosol cyclosporine, standard immune suppression, oral
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Metastatic Breast Cancer
Interventions
Fulvestrant, Everolimus, Placebo
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
25
States / cities
Greenbrae, California • Stanford, California • Rockford, Illinois + 21 more
Conditions
Adult Diffuse Astrocytoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Subependymal Giant Cell Astrocytoma, Recurrent Adult Brain Neoplasm
Interventions
Everolimus, Archival Tissue Analysis
Drug · Other
Lead sponsor
Susan Chang
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
San Francisco, California